Retraction
Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
Paper Information
Record ID:
60618
Author(s):
Journal:
Publication Date:
May 12, 2017
Retraction Date:
January 15, 2025
(<1 year years ago)
Subjects:
Institutions:
- Neurological Disorders Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, PO Box 5825, Doha, Qatar
- Life Sciences Division, College of Science and Engineering, Hamad Bin Khalifa University (HBKU), Education City, Qatar Foundation, PO Box 5825, Doha, Qatar
- Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093, United States
- Department of Biomedical Sciences and Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
- Department of Pathology, University of California, San Diego, La Jolla, CA 92093, United States
- Veterans Affairs San Diego Healthcare System, San Diego, CA 92161, United States
Countries:
Article Type:
Publisher:
Elsevier
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1016/j.nbd.2025.106788Additional Notes:
see also: https://pubpeer.com/publications/E8BFBC4D110BB705D8152DA8AAD90D
Citations (74)
74
Total Citations0
Post-Retraction74
Pre-Retraction0
Same DayFrom experimental studies to computational approaches: recent trends in designing novel therapeutics for amyloidogenesis
Pooja Ghosh, Aritra Kundu, Debabani Ganguly
Journal of Materials Chemistry B
Published: Dec 2024
2 citations
2 citations
34 days before retraction
The humoral immune landscape in Parkinson's disease: Unraveling antibody and B cell changes
Zahra Baridjavadi, Mahmoud Mahmoudi, Narges Abdollahi et al. (7 authors)
Cell Biochemistry and Function
Published: Aug 2024
2 citations
2 citations
141 days before retraction
Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms
Olga Ivanova, Tatiana Karelina
CPT Pharmacometrics & Systems Pharmacology
Open Access
Published: Aug 2024
1 citation
1 citation
145 days before retraction
The Role of Astrocytes and Alpha-Synuclein in Parkinson’s Disease: A Review
David Brash-Arias, Luis I. García, César Antonio Pérez-Estudillo et al. (7 authors)
NeuroSci
Open Access
Published: Mar 2024
5 citations
5 citations
313 days before retraction
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes
Emmanouela Leandrou, Ioanna Chalatsa, Dimitrios Anagnostou et al. (11 authors)
Translational Neurodegeneration
Open Access
Published: Feb 2024
9 citations
9 citations
329 days before retraction
Brain‐Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha‐Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease
Mor Sela, Maria Poley, Patricia Mora‐Raimundo et al. (36 authors)
Advanced Materials
Open Access
Published: Sep 2023
57 citations
57 citations
476 days before retraction
Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson’s disease
Gabriela Henrı́quez, Mahesh Narayan
Exploration of Neuroprotective Therapy
Open Access
Published: Aug 2023
13 citations
13 citations
509 days before retraction
Parkinson's Disease: Current Status, Diagnosis, and Treatment Using Nanomedicines
Ikram Hasan, Shubham Roy, Bing Guo et al. (4 authors)
Advanced Therapeutics
Open Access
Published: May 2023
8 citations
8 citations
600 days before retraction
A functional role for alpha-synuclein in neuroimmune responses
Dustin L. Heiden, Brendan Monogue, Muhammad Ali et al. (4 authors)
Journal of Neuroimmunology
Open Access
Published: Feb 2023
10 citations
10 citations
707 days before retraction
A Mouse Model to Test Novel Therapeutics for Parkinson's Disease: an Update on the Thy1-aSyn (“line 61”) Mice
Franziska Richter, Miloš Stanojlović, Christopher Käufer et al. (5 authors)
Neurotherapeutics
Open Access
Published: Jan 2023
28 citations
28 citations
745 days before retraction
Production of α-Synuclein Fibrillar-Specific scFv from Inclusion Bodies
Vijay Gupta, Issam Hmila, Nishant N. Vaikath et al. (5 authors)
Methods in molecular biology
Published: Jan 2023
745 days before retraction
Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease
Elena Contaldi, Luca Magistrelli, Cristoforo Comi
Handbook of clinical neurology
Published: Jan 2023
2 citations
2 citations
745 days before retraction
Inhibition of α-Synuclein Seeding-Dependent Aggregation by ssDNA Aptamers Specific to C-Terminally Truncated α-Synuclein Fibrils
Issam Hmila, Indulekha P. Sudhakaran, Simona S. Ghanem et al. (7 authors)
ACS Chemical Neuroscience
Published: Nov 2022
8 citations
8 citations
798 days before retraction
Novel naturally occurring autoantibodies attenuate α‐synuclein pathology in a mouse model of Parkinson's disease
Yiming Li, Tao Wang, Lanxia Meng et al. (14 authors)
Neuropathology and Applied Neurobiology
Published: Nov 2022
9 citations
9 citations
803 days before retraction
Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD
Michiyo Iba, Ross McDevitt, Changyoun Kim et al. (12 authors)
Molecular Neurodegeneration
Open Access
Published: Sep 2022
27 citations
27 citations
863 days before retraction
The Role of α-Synuclein in SNARE-mediated Synaptic Vesicle Fusion
Gyeongji Yoo, Yeon‐Kyun Shin, Nam Ki Lee
Journal of Molecular Biology
Open Access
Published: Aug 2022
24 citations
24 citations
896 days before retraction
Therapeutic Insights on Ferroptosis in Parkinson's disease
Komal Thapa, Heena Khan, Neha Kanojia et al. (6 authors)
European Journal of Pharmacology
Published: Jul 2022
57 citations
57 citations
928 days before retraction
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Sindhu Menon, Sabrina E.M. Armstrong, Amir Mohammad Hamzeh et al. (6 authors)
Frontiers in Neurology
Open Access
Published: May 2022
54 citations
54 citations
982 days before retraction
Extracellular alpha-synuclein: Sensors, receptors, and responses
Renato Domingues, Ricardo Sant’Anna, Anna Carolina Carvalho da Fonseca et al. (6 authors)
Neurobiology of Disease
Open Access
Published: Mar 2022
22 citations
22 citations
1032 days before retraction
Conformation-specific Antibodies Targeting Aggregated Forms of α-synuclein Block the Propagation of Synucleinopathy
Min-Sun Choi, Tae-Kyung Kim, Jin-Hyung Ahn et al. (11 authors)
Experimental Neurobiology
Open Access
Published: Feb 2022
8 citations
8 citations
1052 days before retraction
Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease
Alysa Kasen, Christina Houck, Amanda R. Burmeister et al. (6 authors)
Neurobiology of Disease
Open Access
Published: Feb 2022
56 citations
56 citations
1073 days before retraction
Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit <i>in‐vitro</i> seeded aggregation and toxicity
Issam Hmila, Nishant N. Vaikath, Nour K. Majbour et al. (14 authors)
FEBS Journal
Open Access
Published: Jan 2022
19 citations
19 citations
1082 days before retraction
Passive Immunization in Alpha-Synuclein Preclinical Animal Models
Jonas Folke, Nelson Ferreira, Tomasz Brudek et al. (5 authors)
Biomolecules
Open Access
Published: Jan 2022
20 citations
20 citations
1091 days before retraction
Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human α-synuclein: prelude for IND enabling studies
Changyoun Kim, Armine Hovakimyan, Karen Zagorski et al. (17 authors)
npj Vaccines
Open Access
Published: Jan 2022
15 citations
15 citations
1101 days before retraction
Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein
Upasana Ganguly, Sukhpal Singh, Sasanka Chakrabarti et al. (5 authors)
Advances in protein chemistry and structural biology
Published: Jan 2022
3 citations
3 citations
1110 days before retraction
Toward a Disease-Modifying Therapy of Alpha-Synucleinopathies: New Molecules and New Approaches Came into the Limelight
Matthew Upcott, Kirill Chaprov, Vladimir L. Buchman
Molecules
Open Access
Published: Dec 2021
7 citations
7 citations
1139 days before retraction
Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review)
Qingchun Lei, Tingting Wu, Jin Wu et al. (8 authors)
Molecular Medicine Reports
Open Access
Published: Aug 2021
41 citations
41 citations
1248 days before retraction
Current experimental disease-modifying therapeutics for multiple system atrophy
Miguel Lemos, Gregor K. Wenning, Nadia Stefanova
Journal of Neural Transmission
Open Access
Published: Aug 2021
14 citations
14 citations
1248 days before retraction
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
Luís M. A. Oliveira, Thomas Gasser, Robert H. Edwards et al. (20 authors)
npj Parkinson s Disease
Open Access
Published: Jul 2021
120 citations
120 citations
1269 days before retraction
NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson’s disease
Asma Khan, Robert Johnson, Carrie Wittmer et al. (15 authors)
Brain
Open Access
Published: Jun 2021
15 citations
15 citations
1314 days before retraction
Exploring the Release of Toxic Oligomers from α-Synuclein Fibrils with Antibodies and STED Microscopy
Alessandra Bigi, Emilio Ermini, Serene W. Chen et al. (5 authors)
Life
Open Access
Published: May 2021
20 citations
20 citations
1345 days before retraction
The Contribution of Microglia to Neuroinflammation in Parkinson’s Disease
Katja Badanjak, Sonja Fixemer, Semra Smajić et al. (5 authors)
International Journal of Molecular Sciences
Open Access
Published: Apr 2021
209 citations
209 citations
1358 days before retraction
Periphery and brain, innate and adaptive immunity in Parkinson’s disease
Ashley S. Harms, Sara A. Ferreira, Marina Romero‐Ramos
Acta Neuropathologica
Open Access
Published: Feb 2021
216 citations
216 citations
1437 days before retraction
LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress‐Induced Cellular Senescence in Neuronal Cells
Dong Hwan Ho, Daleum Nam, Mi Kyoung Seo et al. (6 authors)
Oxidative Medicine and Cellular Longevity
Open Access
Published: Jan 2021
25 citations
25 citations
1475 days before retraction
Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors
Inês Caldeira Brás, Tiago F. Outeiro
International review of movement disorders
Published: Jan 2021
1475 days before retraction
Alpha‐Synuclein oligomerization and aggregation: All models are useful but only if we know what they model
Hilal A. Lashuel
Journal of Neurochemistry
Open Access
Published: Dec 2020
7 citations
7 citations
1489 days before retraction
The Role of α-Synuclein Oligomers in Parkinson’s Disease
Xiaoyu Du, Xi-xiu Xie, Rui‐tian Liu
International Journal of Molecular Sciences
Open Access
Published: Nov 2020
177 citations
177 citations
1520 days before retraction
Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies
Vijay Gupta, Indulekha P. Sudhakaran, Zeyaul Islam et al. (8 authors)
PLoS ONE
Open Access
Published: Nov 2020
11 citations
11 citations
1531 days before retraction
Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions
Anne-Marie Castonguay, Claude Gravel, Martin Lévesque
Journal of Parkinson s Disease
Open Access
Published: Oct 2020
46 citations
46 citations
1545 days before retraction
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
Miguel Lemos, Serena Venezia, Violetta Refolo et al. (13 authors)
Translational Neurodegeneration
Open Access
Published: Sep 2020
29 citations
29 citations
1574 days before retraction
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
Maria Fouka, Panagiota Mavroeidi, Grigoria Tsaka et al. (4 authors)
Frontiers in Cell and Developmental Biology
Open Access
Published: Sep 2020
18 citations
18 citations
1594 days before retraction
Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
Vijay Gupta, Safa Salim, Issam Hmila et al. (13 authors)
Scientific Reports
Open Access
Published: May 2020
14 citations
14 citations
1703 days before retraction
Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
Michiyo Iba, Changyoun Kim, Jazmin Florio et al. (9 authors)
Frontiers in Neuroscience
Open Access
Published: Mar 2020
22 citations
22 citations
1751 days before retraction
Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Margaux Teil, Marie-Laure Arotçarena, Emilie Faggiani et al. (6 authors)
Biomolecules
Open Access
Published: Mar 2020
59 citations
59 citations
1779 days before retraction
Synucleinopathies: Where we are and where we need to go
Inês Caldeira Brás, Antonio Dominguez‐Meijide, Ellen Gerhardt et al. (9 authors)
Journal of Neurochemistry
Open Access
Published: Jan 2020
85 citations
85 citations
1822 days before retraction
Half a century of amyloids: past, present and future
Pu Chun Ke, Ruhong Zhou, Louise C. Serpell et al. (15 authors)
Chemical Society Reviews
Open Access
Published: Jan 2020
496 citations
496 citations
1841 days before retraction
Peri‐arterial pathways for clearance of α‐Synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapy
Jacqui Nimmo, David A. Johnston, Jean‐Cosme Dodart et al. (8 authors)
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Open Access
Published: Jan 2020
23 citations
23 citations
1841 days before retraction
Active poly‐GA vaccination prevents microglia activation and motor deficits in a <i>C9orf72</i> mouse model
Qihui Zhou, Nikola Mareljic, Meike Michaelsen et al. (18 authors)
EMBO Molecular Medicine
Open Access
Published: Dec 2019
55 citations
55 citations
1853 days before retraction
Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease
Michael X. Henderson, Dustin J. Covell, Charlotte Hiu-Yan Chung et al. (14 authors)
Neurobiology of Disease
Open Access
Published: Dec 2019
41 citations
41 citations
1857 days before retraction
The good and bad of therapeutic strategies that directly target α‐synuclein
Francesca Longhena, Gaia Faustini, Viviana Brembati et al. (5 authors)
IUBMB Life
Open Access
Published: Nov 2019
9 citations
9 citations
1897 days before retraction
Quick Stats
Total Citations:
74
Years Since Retraction:
<1 year
Open Access:
Yes
Last Checked:
Jul 24, 2025